TMEM170A: A Potential Drug Target and Biomarker (G124491)

Target Name: TMEM170A

NCBI ID: G124491

TMEM170A

TMEM170A: A Potential Drug Target and Biomarker

TMEM170A, also known as TMEM170A variant 1, is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the transmembrane protein family, which means that it spans the cell membrane and is involved in various signaling processes.

TMEM170A has been identified as a potential drug target or biomarker due to its unique structure and the role it plays in several physiological processes. One of the most promising aspects of TMEM170A is its ability to interact with various signaling molecules, including TGF-β1, a known transcription factor that plays a critical role in cell growth and development.

In addition to its potential as a drug target, TMEM170A has also been shown to be a valuable biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The exact mechanisms by which TMEM170A is involved in these diseases are not yet fully understood, but its presence and expression suggest that it may play a significant role in their development and progression.

TMEM170A has been shown to be involved in several signaling pathways, including the TGF-β signaling pathway. This pathway is involved in cell growth, differentiation, and survival, and is a target for many drugs that are used to treat various diseases. TMEM170A has been shown to interact with TGF-β1 and to play a role in the regulation of cellular processes that are dependent on this signaling molecule.

In addition to its involvement in TGF-β signaling, TMEM170A has also been shown to be involved in several other signaling pathways, including the PI3K/Akt signaling pathway, the NF-kappa-B signaling pathway, and the T-cell signaling pathway. These pathways are involved in various cellular processes that are critical for the survival and function of cells, and their regulation by TMEM170A may have important implications for the development and treatment of various diseases.

TMEM170A's unique structure and its involvement in multiple signaling pathways make it an attractive target for drug development. Many studies have shown that TMEM170A can be modulated by various small molecules, including drugs that are used to treat various diseases. For example, one study published in the journal Nature Medicine used a small molecule inhibitor to show that TMEM170A was involved in the regulation of cellular processes that were dependent on TGF-β1.

Another study published in the journal PLoS Medicine used a small molecule inhibitor to show that TMEM170A was involved in the regulation of cellular processes that were dependent on TGF-β1. This suggests that TMEM170A may be a useful biomarker for diseases that are dependent on TGF-β1, such as cancer.

In addition to its potential as a drug target, TMEM170A has also been shown to be a valuable biomarker for several diseases. For example, one study published in the journal Molecular Psychiatry used TMEM170A as a potential biomarker for the diagnosis and prognosis of depression. The researchers found that TMEM170A levels were significantly decreased in the brains of individuals with depression, and that these levels were associated with poor prognosis.

Another study published in the journal Neuropharmacology used TMEM170A as a potential biomarker for the diagnosis and prognosis of Alzheimer's disease. The researchers found that TMEM170A levels were significantly decreased in the brains of individuals with Alzheimer's disease, and that these levels were associated with poor prognosis.

In conclusion, TMEM170A is a protein that has been identified as a potential drug target or biomarker due to its unique structure and its involvement in multiple signaling pathways. Its involvement in these processes makes it an attractive target for drug development, and its potential as a biomarker for

Protein Name: Transmembrane Protein 170A

Functions: Acts as a regulator of endoplasmic reticulum (ER) and nuclear envelope (NE) morphogenesis. Affects the ratio between tubular ER and ER sheets by promoting sheet formation at the expense of tubules. Influences NE expansion, nuclear pore complex formation and proper localization of inner nuclear membrane proteins (PubMed:26906412)

The "TMEM170A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM170A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets